R
R

Regeneron


財經新聞

Sanofi targets Dupixent peak sales of over 13 bln euros

PARIS, March 29 (Reuters) - French healthcare group Sanofi SASY.PA , which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion). "This new ambition does not include potential for additional sales ambition upgrade from chronic obst
G
R
S

Healthcare group Sanofi targets Dupixent peak sales of over 13 bln euros

PARIS, March 29 (Reuters) - French healthcare group Sanofi SASY.PA , which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion). "This new ambition does not include potential for additional sales ambition upgrade from chronic obst
G
R
S

Tech and healthcare help European shares above one-month highs

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * STOXX 600 set to end 2021 21.7% higher, fell 4% in 2020 * CNH Industrial hits record high * Defensives lead gains * Roche up after approval for COVID-19 products (Updates with closing prices) By Anisha Sircar Dec 27 (Reuters) - European sh
R
R
C
U
E
F
U
G

EU regulator builds Omicron defences with approvals of Vir, Sobi drugs

* EMA approves Kineret and Xevudy for COVID-19 treatment * Kineret for adults with pneumonia, lung failure risk * Xevudy for adults, adolescents at risk of severe disease By Pushkala Aripaka and Amna Karimi Dec 16 (Reuters) - The European Union's drug regulator on Thursday approved a COVID-19 treatment from British-U.S. duo GSK GSK.L and Vir Biotec
A
G
G
P
R
R
S

AstraZeneca therapy works against Omicron; results mixed for Regeneron

* Evusheld retains neutralising activity against Omicron * REGEN-COV showed diminished potency; active against Delta * More data on AstraZeneca's Evusheld expected 'very soon' (Writes through with details on AstraZeneca's drug, background) By Mrinalika Roy and Pushkala Aripaka Dec 16 (Reuters) - AstraZeneca AZN.L and Regeneron REGN.O on Thursday re
A
G
R

Oil rises around 2% on strong U.S. demand, upbeat Fed outlook

* Upbeat U.S. Federal Reserve boosts risk appetite * U.S. crude inventories drop more than expected, demand surges * Saudi Arabia's October crude oil exports hit 18-month high * Britain, South Africa post biggest rise in daily COVID-19 cases (Updates with settlement prices, market activity) By Stephanie Kelly NEW YORK, Dec 16 (Reuters) - Oil prices
A
C
R
O
B

Lab tests: Eli Lilly, Regeneron antibody therapies lose out against Omicron

By Ludwig Burger FRANKFURT, Dec 14 (Reuters) - German researchers have found that COVID-19 therapies developed by Eli Lilly LLY.N and Regeneron REGN.O lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus, likely reducing treatment options if the new variant prevails. Two groups of Germany based sci
A
G
P
R
S

What you need to know about the coronavirus right now

Dec 14 (Reuters) - Here's what you need to know about the coronavirus right now: Pfizer vaccine less effective against hospitalisation - study Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, according to a major real-world study which suggests weaker effica
G
P
R

Lab test: Eli Lilly, Regeneron antibody therapies lose out against Omicron

By Ludwig Burger FRANKFURT, Dec 14 (Reuters) - German researchers have found that COVID-19 therapies developed by Eli Lilly LLY.N and Regeneron REGN.O lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of coronavirus. The group of Cologne and Berlin-based scientists found that protection from GlaxoSmithKline GS
A
G
R
S

GSK says tests indicate antibody drug works against Omicron

* Sotrovimab, developed with Vir, tested in lab and on hamsters * Key Omicron mutations did not elude drug activity in study * Tests continuing on further mutations By Ludwig Burger Dec 2 (Reuters) - Laboratory analysis of the antibody-based COVID-19 therapy GlaxoSmithKline GSK.L (GSK) is developing with U.S. partner Vir VIR.O has indicated the dru
A
G
R
S

Yen, Swiss franc rally on global outlook risks after hawkish Powell

* Fed's Powell says risks of inflation rising * Fed's Powell says may accelerate pace of bond taper * Omicron risks weigh on market sentiment * Graphic: World FX rates Link By Caroline Valetkevitch and Gertrude Chavez-Dreyfuss NEW YORK, Nov 30 (Reuters) - The safe-haven yen and Swiss Franc gained on Tuesday, with risk appetite plummeting, as invest
A
E
E
E
E
E
E
E
R
U
U

Officials offer vaccine reassurance; WHO advises against travel bans

* Moderna CEO warns of 'material drop' in vaccine effectiveness * Markets fall on fears of prolonged COVID-19 pandemic * Time needed to know if vaccines work against Omicron * Japan and Brazil report first cases of new variant By Ludwig Burger and Emma Thomasson FRANKFURT/BERLIN, Nov 30 (Reuters) - The World Health Organization warned countries on
A
P
R
U
U

UK Stocks-Factors to watch on Aug. 20

Aug 20 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening 11 points higher on Friday, according to financial bookmakers, with futures FFIc1 up 0.22%. * ASTRAZENECA: AstraZeneca AZN.L said its antibody therapy met the main goal of preventing COVID-19 infection in a late-stage study. * MARKS & SPENCER: British retailer Marks & Spencer MKS.L s
A
M
R
R
B
U

What you need to know about the coronavirus right now

June 18 (Reuters) - Here's what you need to know about the coronavirus right now: Global COVID-19 death toll exceeds 4 million Coronavirus-related deaths worldwide passed 4 million on Thursday, according to a Reuters tally, as many countries struggle to procure enough vaccines to inoculate their populations. It took over a year for the COVID-19 dea
A
P
R

Europe secures 55,000 doses of Roche-Regeneron COVID drug hope

By Francesco Guarascio and John Miller BRUSSELS, June 3 (Reuters) - The European Union has secured about 55,000 doses of a potential treatment for COVID-19 based on a cocktail of monoclonal antibodies developed by U.S. drugmaker Regeneron REGN.O and Swiss pharmaceutical giant Roche ROG.S , an EU spokesman said. The deal is the bloc's first contract
G
R
R



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明